# Developing Pathogen Recognition Receptor Agonists as Latency Reversing Agents

> **NIH NIH R01** · GEORGE WASHINGTON UNIVERSITY · 2020 · $398,750

## Abstract

The existence of latent reservoirs of HIV-infected cells constitutes the major impediment towards viral
eradication. HIV-1 latent reservoirs are small, but extremely long-lived. Latent infection is associated with
undetectable levels of viral gene expression and appears to be non-cytopathic. However, upon reactivation,
latent viruses enter an active mode of replication in which they are fully competent for spread and induction of
disease. The current thinking in the field is that a combination of hypothetical drugs that will reactivate latent
viruses (Latency Reversing Agent or LRA), with present-day antiretroviral drugs, will be an effective approach
toward viral eradication. We have previously found that Pam3CSK4, a TLR-1/2 agonist, can reactivate latent
HIV-1. Based on this earlier finding, we propose to further investigate the possibility of developing Pathogen
Recognition Receptor (PRR) agonists as novel strategies to reactivate/eradicate latent HIV-1 infection.
 In Aim 1, we plan to characterize the ability of multi-PRR agonists to reactivate latent HIV-1. Multi-PRR
agonists are synthetic TLR agonists developed by InvivoGen to be used as adjuvants in cancer therapy,
infectious diseases and vaccination. Our preliminary data using the tumoral cell line JLat, a primary model of
HIV-1 latency (Cultured TCM model) and cells isolated from aviremic patients demonstrate that these ligands
have the ability to reactivate latent HIV-1. Furthermore, in this aim we also plan to evaluate the potential of this
agonist to reduce the latent reservoir in vitro. We have found that dynasore, a GTPase inhibitor, has the ability
to reactivate latent HIV-1. It has been proposed that dynasore activates the PRR mitochondria antiviral signal
protein (MAVS). We have further corroborated this result. Based on this notion, this aim is designed to
characterize whether manipulation of the RIG-I/MDA-5/MAVS pathway can have therapeutic implications
towards HIV-1 eradication. First, we are going to study whether RIG-1 and MDA-5 ligands that signal through
MAVS can reactivate latent HIV-1. Second, it has been shown that the HIV-1 protease can induce lysosomal
degradation of RIG-I to avoid sensing and the induction of an interferon response. We plan to characterize
whether this mechanism is involved in the establishment of latency. Lastly, identifying novel mechanisms that
are involved in the maintenance of latency would lead to the design of novel therapeutic approaches. We have
performed a screening to identify epigenetic modulators that synergize with the synthetic TLR-2 ligand CL572.
We have identified several pathways that synergize with CL572. In Aim 3, we plan to characterize in detail the
mechanism of synergy between PRR agonists and two known pathways, HDACs and bromodomain proteins,
and two novel pathways, O6-Methylguanine-DNA methyltransferase and sirtuin-1 and -2.
 The overall goal of this proposal is to move forward novel targets that can be exploited therapeutic...

## Key facts

- **NIH application ID:** 9955178
- **Project number:** 5R01AI124722-06
- **Recipient organization:** GEORGE WASHINGTON UNIVERSITY
- **Principal Investigator:** Alberto Bosque
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $398,750
- **Award type:** 5
- **Project period:** 2016-07-01 → 2022-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9955178

## Citation

> US National Institutes of Health, RePORTER application 9955178, Developing Pathogen Recognition Receptor Agonists as Latency Reversing Agents (5R01AI124722-06). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/9955178. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*